ARGENX SE
No SEC Form 4 filings for $ARGX in the last 30 days.
See all $ARGX insider activity →Forte Biosciences (FBRX) is scheduled to report Q2 earnings Aug. 17, with analysts expecting a loss of $1.01 per share on zero revenue. The company is being acquired by argenx for $77 per share in cash, with the tender offer set to expire Aug. 26. Deal progress and cash/clinical updates are key for investors.
Forte Biosciences (FBRX) reported a $45.5 million net loss for the six months ended June 30, 2026, up from $26.9 million a year earlier, citing higher FB102 clinical and manufacturing spending. Cash and investments totaled $198.5 million after a $172.5 million April 2026 equity offering. Forte agreed to be acquired by argenx via a $77-per-share cash tender offer and merger.
Belgium’s BEL 20 closed up 0.07% as traders pared rate hike bets after an in-line July CPI report. Financials, telecoms and technology led. KBC Groep rose 1.85% to 129.65, Argen-X gained 1.60% to 761.00, and Umicore added 1.34% to 24.22. UCB fell 1.95% to 221.80; AB Inbev and GBL also declined.
Over the past 7 days, alphai's AI scored 2 news stories mentioning ARGX (ARGENX SE). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent ARGX coverage spans mergers & acquisitions, macro economy and technology.
Forte Biosciences (FBRX) is scheduled to report Q2 earnings Aug. 17, with analysts expecting a loss of $1.01 per share on zero revenue. The company is being acquired by argenx for $77 per share in cash, with the tender offer set to expire Aug. 26. Deal progress and cash/clinical updates are key for investors.
Forte Biosciences (FBRX) reported a $45.5 million net loss for the six months ended June 30, 2026, up from $26.9 million a year earlier, citing higher FB102 clinical and manufacturing spending. Cash and investments totaled $198.5 million after a $172.5 million April 2026 equity offering. Forte agreed to be acquired by argenx via a $77-per-share cash tender offer and merger.
ARGX outperformed on the day, but the article provides no ARGX-specific catalyst beyond the market-wide move.
Deal is a material growth bet to extend the post-Vyvgart runway, but investor reaction was lukewarm and execution risk remains until Q3 close.
The tender offer is a concrete M&A catalyst that could shift argenx’s pipeline mix and investor expectations around diversification beyond Vyvgart.
alphai scores every news story that mentions ARGX with an AI model for sentiment and relevance, and aggregates insider trades from ARGENX SE's SEC EDGAR Form 4 filings. Figures refresh continuously.
Forte Biosciences (FBRX) is scheduled to report Q2 earnings Aug. 17, with analysts expecting a loss of $1.01 per share on zero revenue. The company is being acquired by argenx for $77 per share in cash, with the tender offer set to expire Aug. 26. Deal progress and cash/clinical updates are key for investors.
6 min readForte Biosciences (FBRX) reported a $45.5 million net loss for the six months ended June 30, 2026, up from $26.9 million a year earlier, citing higher FB102 clinical and manufacturing spending. Cash and investments totaled $198.5 million after a $172.5 million April 2026 equity offering. Forte agreed to be acquired by argenx via a $77-per-share cash tender offer and merger.
6 min readBelgium’s BEL 20 closed up 0.07% as traders pared rate hike bets after an in-line July CPI report. Financials, telecoms and technology led. KBC Groep rose 1.85% to 129.65, Argen-X gained 1.60% to 761.00, and Umicore added 1.34% to 24.22. UCB fell 1.95% to 221.80; AB Inbev and GBL also declined.
2 min readArgenx SE (ARGX) agreed to buy Forte Biosciences (FBRX) for about $2.2 billion in cash, offering $77 per share, a ~40% premium to Forte’s prior close. The deal includes Forte’s FB102 anti-CD122 antibody and is expected to close in Q3 2026, pending approvals. Both boards approved.
6 min readargenx (ARGX) launched a tender offer to acquire Forte Biosciences, with Forte’s board backing the deal, according to the companies. Forte shareholders can choose to sell shares into argenx’s bid under agreed terms. The move adds the FB102 CD122 antibody program and is positioned as pipeline expansion beyond Vyvgart, with potential implications for growth and concentration risk.
4 min readArgenx said it is partnering with Monash University and Myostellar to develop muscular therapies, citing a new research collaboration that expands its access to Australia’s research community. The announcement is attributed to argenx’s general manager for Australia, Kathryn Evans.
2 min readargenx (ARGX) said its subsidiary Avena Merger Sub has started a tender offer to buy all outstanding Forte Biosciences (FBRX) shares for $77.00 per share in cash, net to the seller, under a July 26, 2026 merger agreement. The offer expires Aug. 26, 2026 unless extended, and Forte’s board recommends acceptance.
5 min readArgenx (ARGX) said it will acquire Forte Biosciences (FBRX) for $77 per share, announced July 27. The article says FBRX began unusual price movement on June 29, weeks before the deal, and notes similar trading activity in ARGX. It cites company valuations of about $1.06 billion for FBRX and $54.57 billion for ARGX.
6 min readA weekly healthcare roundup cites multiple corporate events: Cipla and Viatris received U.S. FDA approvals, Boston Scientific announced job cuts, argenx agreed to acquire Forte Biosciences, and Johnson & Johnson and GSK reached deal terms. It highlights regulatory, M&A, and restructuring developments that can affect sector sentiment and individual stock performance.
4 min readThe article discusses Argenx’s $2.2 billion bet via a deal with Forte Biosciences, focused on Forte’s FB102 anti-CD122 antibody for autoimmune diseases including celiac, vitiligo, and alopecia areata. It notes early celiac data and expected clinical readouts later in the year, while citing share pressure from an equity raise and delayed vitiligo timing.
3 min read
